Topline results of the STRONG-HF trial point to significant clinical benefit from a strategy featuring early initiation and rapid uptitration of meds for patients hospitalized with heart failure.
Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.
Hyperkalemia is no reason for suboptimal guideline-directed heart failure medical therapy, given availability of at least one potassium-binding drug that seems to offer protection, researchers say.
There were fewer cardiac events at 2 years for MI patients with LVEF 40% to 49% discharged on beta blockers and, separately, renin-angiotensin-system inhibitors in a propensity-matched cohort study.